Akihito Yokoyama

Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials

Nicola A. Hanania, Phillip E. Korenblat, Kenneth R. Chapman et al. · The Lancet Respiratory Medicine · 2016 · 463 citations

Asthma, Rheumatology, Allergy +10

Comparative Study of KL-6, Surfactant Protein-A, Surfactant Protein-D, and Monocyte Chemoattractant Protein-1 as Serum Markers for Interstitial Lung Diseases

Hiroshi Ohnishi, Akihito Yokoyama, Keiichi Kondo et al. · American Journal of Respiratory and Critical Care Medicine · 2002 · 399 citations

Inflammation, Inflammatory Lung Disease, Advanced Lung Disease +14

Prognostic value of circulating KL‐6 in idiopathic pulmonary fibrosis

Akihito Yokoyama, Keiichi Kondo, Masamitsu Nakajima et al. · Respirology · 2006 · 299 citations

KL-6, a Mucin-like Glycoprotein, in Bronchoalveolar Lavage Fluid from Patients with Interstitial Lung Disease

Nobuoki Kohno, Yukikazu Awaya, Tetsu Oyama et al. · American Review of Respiratory Disease · 1993 · 288 citations

Asthma, Inflammatory Lung Disease, Advanced Lung Disease +18

AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo

Jing Yang, Takayuki Ikezoe, Chie Nishioka et al. · Blood · 2007 · 284 citations · Full text